Therapeutics Targeting FGF Signaling Network in Human Diseases

Trends in Pharmacological Sciences

Volumn 37, Issue 12, 2016, Pages 1081-1096

  Katoh, Masaru ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

epithelial to mesenchymal transition; erdafitinib; immune checkpoint blocker; infigratinib; miRNA; myeloproliferative syndrome.

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASP 5878; AZD 4547; BAY 1179470; BUROSUMAB; CD135 ANTIGEN; DEBIO 1347; DOVITINIB; E 7090; EPIDERMAL GROWTH FACTOR RECEPTOR; ERDAFITINIB; FIBROBLAST GROWTH FACTOR; FP 1039; FPA 144; INFIGRATINIB; LY 2874455; MFGR 1877S; PALIFERMIN; PONATINIB; PROTEIN INHIBITOR; RIFERMINOGENE PECAPLASMID; SPRIFERMIN; TAS 120; TRAFERMIN; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR RECEPTOR;

ANGIOGENESIS; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASES; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC VARIATION; GERMLINE MUTATION; HUMAN; IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ORAL MUCOSITIS; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ULCER; UPREGULATION; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; COST BENEFIT ANALYSIS; DRUG DESIGN; DRUG EFFECTS; ECONOMICS; GENE THERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; COST-BENEFIT ANALYSIS; DRUG DESIGN; FIBROBLAST GROWTH FACTORS; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84995785776     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.003     Document Type: Review

References (109)

1. 1 Katoh, M., Nakagama, H., FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34 (2014), 280–300.
2. 2 Carter, E.P., et al. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 25 (2015), 221–233.
3. 3 Ornitz, D.M., Itoh, N., The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4 (2015), 215–266.
4. 4 Eswarakumar, V.P., et al. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16 (2005), 139–149.
5. 5 Grose, R., Dickson, C., Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16 (2005), 179–186.
6. 6 Wilkie, A.O., Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 16 (2005), 187–203.
7. 7 Vajo, Z., et al. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 21 (2000), 23–39.
8. 8 Sonvilla, G., et al. FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis 29 (2008), 15–24.
9. 9 Holdman, X.B., et al. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res., 17, 2015, 141.
10. 10 Jain, R.K., Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31 (2013), 2205–2218.
11. 11 Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12 (2012), 237–251.
12. 12 Faul, C., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121 (2011), 4393–4408.
13. 13 Belperio, J., et al. Inflammatory mediators and clinical outcome in patients with advanced heart failure receiving cardiac resynchronization therapy. Am. J. Cardiol. 117 (2016), 617–625.
14. 14 Katoh, M., Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks. Int. J. Mol. Med. 32 (2013), 763–767.
15. 15 Suh, J.M., et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513 (2014), 436–439.
16. 16 Melville, H., et al. Genetic basis of potential therapeutic strategies for craniosynostosis. Am. J. Med. Genet. 152A (2010), 3007–3015.
17. 17 Roscioli, T., et al. Genotype and clinical care correlations in craniosynostosis: findings from a cohort of 630 Australian and New Zealand patients. Am. J. Med. Genet. 163C (2013), 259–270.
18. 18 Foldynova-Trantirkova, S., et al. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat. 33 (2012), 29–41.
19. 19 Helsten, T., et al. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 34 (2015), 479–496.
20. 20 Maher, G.J., et al. Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 2454–2459.
21. 21 Kim, S.H., et al. Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome. J. Neuroendocrinol. 20 (2007), 141–163.
22. 22 Shams, I., et al. Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway. Mol. Cell. Biol. 27 (2007), 6903–6912.
23. 23 Campbell, T.M., et al. FGFR2 risk SNPs confer breast cancer risk by augmenting estrogen responsiveness. Carcinogenesis 37 (2016), 741–750.
24. 24 Katoh, M., et al. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 328 (2013), 198–206.
25. 25 Choucair, N., et al. 10q26.1 microdeletion: redefining the critical regions for microcephaly, genital anomalies. Am. J. Med. Genet. 167A (2015), 2707–2713.
26. 26 Katoh, M., Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy. Epigenomics 8 (2016), 285–305.
27. 27 Mutsaers, H.A., et al. Switch in FGFR3 and -4 expression profile during human renal development may account for transient hypercalcemia in patients with Sotos syndrome due to 5q35 microdeletions. J. Clin. Endocrinol. Metab. 99E (2014), 1361–1367.
28. 28 Bennett, J.T., et al. Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis. Am. J. Hum. Genet. 98 (2016), 579–587.
29. 29 Kiritsi, D., et al. Blaschko line acne on pre-existent hypomelanosis reflecting a mosaic FGFR2 mutation. Br. J. Dermatol. 172 (2015), 1125–1127.
30. 30 Hafner, C., et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 116 (2006), 2201–2207.
31. 31 Schäfer, M.H., et al. Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Hum. Pathol. 46 (2015), 1488–1495.
32. 32 Ross, J.S., et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27 (2014), 271–280.
33. 33 Cancer Genome Atlas Research Network, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
34. 34 André, F., Cortés, J., Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res. Treat. 150 (2015), 1–8.
35. 35 Helsten, T., et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22 (2016), 259–267.
36. 36 Katoh, M., FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis. Int. J. Mol. Med. 38 (2016), 3–15.
37. 37 Gallo, L.H., et al. Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 26 (2015), 425–449.
38. 38 Agelopoulos, K., et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma. Clin. Cancer Res. 21 (2015), 4935–4946.
39. 39 Patani, H., et al. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget 7 (2016), 24252–24268.
40. 40 Gartside, M.G., et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 7 (2009), 41–54.
41. 41 Metzner, T., et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J. Invest. Dermatol. 131 (2011), 2087–2095.
42. 42 Gelsi-Boyer, V., et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol. Cancer Res. 3 (2005), 655–667.
43. 43 Rooney, C., et al. Characterization of FGFR1 locus in sqNSCLC reveals a broad and heterogeneous amplicon. PLoS One, 11, 2016, e0149628.
44. 44 Kaiser, M.F., et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27 (2013), 1754–1757.
45. 45 Schelch, K., et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am. J. Respir. Crit. Care Med. 190 (2014), 763–772.
46. 46 Blackwell, C., et al. Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. Oncotarget., 2016, 10.18632/oncotarget.9515 Published online May 20, 2016.
47. 47 Mok, Y., et al. From epistaxis to bone pain: report of two cases illustrating the clinicopathological spectrum of phosphaturic mesenchymal tumour with fibroblast growth factor receptor 1 immunohistochemical and cytogenetic analyses. Histopathology 68 (2016), 925–930.
48. 48 Garcia, C.B., et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT–SSX2. Oncogene 31 (2012), 2323–2334.
49. 49 Rafii, S., et al. Angiocrine functions of organ-specific endothelial cells. Nature 529 (2016), 316–325.
50. 50 House, S.L., et al. Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 310H (2016), 559–571.
51. 51 Allerstorfer, S., et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 27 (2008), 4180–4190.
52. 52 Haddad, L.E., et al. Characterization of FGF receptor expression in human neutrophils, their contribution to chemotaxis. Am. J. Physiol. Cell Physiol. 301C (2011), 1036–1045.
53. 53 Rossaint, J., et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J. Clin. Invest. 126 (2016), 962–974.
54. 2 D in macrophages. FEBS Lett. 590 (2016), 53–67.
55. 55 Chen, P.Y., et al. FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2 (2012), 1684–1696.
56. 56 Jetten, N., et al. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 17 (2014), 109–118.
57. 57 Degirolamo, C., et al. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15 (2016), 51–69.
58. 58 El Agha, E., et al. Role of fibroblast growth factors in organ regeneration and repair. Semin. Cell Dev. Biol. 53 (2016), 76–84.
59. 59 Zhang, J., Li, Y., Therapeutic uses of FGFs. Semin. Cell Dev. Biol. 53 (2016), 144–154.
60. 60 Belch, J., et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377 (2011), 1929–1937.
61. 61 McNelis, J.C., Olefsky, J.M., Macrophages, immunity, and metabolic disease. Immunity 41 (2014), 36–48.
62. 62 Fuchsberger, C., et al. The genetic architecture of type 2 diabetes. Nature 536 (2016), 41–47.
63. 63 Tolcher, A.W., et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann. Oncol. 27 (2016), 526–532.
64. 64 Garcia, S., et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med., 5, 2013, 203ra124.
65. 65 Carpenter, T.O., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 124 (2014), 1587–1597.
66. 66 Gavine, P.R., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72 (2012), 2045–2056.
67. 67 Porta, C., et al. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol. 11 (2015), 39–50.
68. 68 Verstraete, M., et al. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer, 15, 2015, 946.
69. 69 Guagnano, V., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2 (2012), 1118–1133.
70. 70 O'Hare, T., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16 (2009), 401–412.
71. 71 Ochiiwa, H. et al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Mol Cancer Ther 12 (11 Suppl.), Abstract nr A270.
72. 72 Futami, T., et al. Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in FGF19-expressing hepatocellular carcinoma. Mol Cancer Ther., 14(Suppl. 2), 2015 Abstract nr A172.
73. 73 Nakanishi, Y., et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol. Cancer Ther. 13 (2014), 2547–2558.
74. 74 Miyano, S., Characterization of E7090: a novel and selective FGFR inhibitor. Cancer Res., 76(14 Suppl.), 2015 Abstract nr 3778.
75. 75 Zhao, G., et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 10 (2011), 2200–2210.
76. 76 Tan, L., et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E4869–E4877.
77. 77 Hagel, M., et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5 (2015), 424–437.
78. 78 Tanner, Y., Grose, R.P., Dysregulated FGF signaling in neoplastic disorders. Semin. Cell Dev. Biol. 53 (2016), 126–135.
79. 79 Wöhrle, S., et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J. Bone Miner. Res. 28 (2013), 899–911.
80. 80 Komla-Ebri, D., et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J. Clin. Invest. 126 (2016), 1871–1884.
81. 81 Mano, H., ALKoma: a cancer subtype with a shared target. Cancer Discov. 2 (2012), 495–502.
82. 82 Katayama, R., et al. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin. Cancer Res. 21 (2015), 2227–2235.
83. 83 Camidge, D.R., et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11 (2014), 473–481.
84. 84 Costa, D.B., Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl. Lung Cancer Res. 5 (2016), 331–337.
85. 85 Smith, C.C., et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5319–5324.
86. 86 Smith, C.C., et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 ‘gatekeeper’ F691L mutation with PLX3397. Cancer Discov. 5 (2015), 668–679.
87. 87 da Silva-Diz, V., et al. Cancer stem-like cells act via distinct signaling pathways in promoting late stages of malignant progression. Cancer Res. 76 (2016), 1245–1259.
88. 88 Ware, K.E., et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2–FGFR1 autocrine growth loop. Oncogenesis, 2, 2013, e39.
89. 89 André, F., et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 19 (2013), 3693–3702.
90. 90 Pearson, A., et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6 (2016), 838–851.
91. 91 Di Stefano, A.L., et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21 (2015), 3307–3317.
92. 92 Tabernero, J., et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 33 (2015), 3401–3408.
93. 93 Touat, M., et al. Targeting FGFR signaling in cancer. Clin. Cancer Res. 21 (2015), 2684–2694.
94. 94 Okazaki, T., Honjo, T., PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19 (2007), 813–824.
95. 95 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
96. 96 Warzecha, C.C., et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell 33 (2009), 591–601.
97. 97 Horvath, A., et al. Novel insights into breast cancer genetic variance through RNA sequencing. Sci. Rep., 3, 2013, 2256.
98. 98 Liang, Y.C., et al. The impact of RNA binding motif protein 4-regulated splicing cascade on the progression and metabolism of colorectal cancer cells. Oncotarget 6 (2015), 38046–38060.
99. 99 Wendt, M.K., et al. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res., 16, 2014, R24.
100. 100 Ranieri, D., et al. HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition. Int. J. Cancer 137 (2015), 61–72.
101. 101 Wang, L., et al. miR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget 6 (2015), 35978–35990.
102. 102 Katoh, M., Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non–cancerous and cancerous diseases. Front. Cell Dev. Biol., 2, 2014, 61.
103. 103 Wang, F., et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 6 (2015), 7899–7917.
104. 104 Guan, X., et al. miR-223 regulates adipogenic and osteogenic differentiation of mesenchymal stem cells through a C/EBPs/miR-223/FGFR2 regulatory feedback loop. Stem Cells 33 (2015), 1589–1600.
105. 105 Parker, B.C., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 123 (2013), 855–865.
106. 106 Xu, Q., et al. Long non-coding RNA regulation of epithelial–mesenchymal transition in cancer metastasis. Cell Death Dis., 7, 2016, e2254.
107. 107 Gonzalez, I., et al. A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat. Struct. Mol. Biol. 22 (2015), 370–376.
108. 108 Sun, J., et al. Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3. Mol. Biol. Rep. 43 (2016), 427–436.
109. 109 Doble, B., Budget impact and cost-effectiveness: can we afford precision medicine in oncology?. Scand. J. Clin. Lab. Invest. 18 (2016), 1–6.